Andarine (developmental code names GTx-007, S-4) is an investigational selective androgen receptor modulator developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy,[1] using the nonsteroidal antiandrogen bicalutamide as a lead compound.